A study of ACER-002 (celiprolol hydrochloride) for the treatment of vascular Ehlers-Danlos Syndrome (vEDS).

Trial Profile

A study of ACER-002 (celiprolol hydrochloride) for the treatment of vascular Ehlers-Danlos Syndrome (vEDS).

Planning
Phase of Trial: Phase III

Latest Information Update: 20 May 2016

At a glance

  • Drugs Celiprolol (Primary)
  • Indications Ehlers-Danlos syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 May 2016 New trial record
    • 10 May 2016 According to an Acer Therapeutics media release, the company plans to file an NDA based on a randomized, controlled clinical study of celiprolol.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top